319 related articles for article (PubMed ID: 2514093)
21. High-level expression of active human plasminogen activator inhibitor type 1 (PAI-1) in E. coli.
Zhou A; Pei Y; Wu H; Dong X; Xu X
Biochem Mol Biol Int; 1996 May; 39(2):235-42. PubMed ID: 8799449
[TBL] [Abstract][Full Text] [Related]
22. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor.
Adams DS; Griffin LA; Nachajko WR; Reddy VB; Wei CM
J Biol Chem; 1991 May; 266(13):8476-82. PubMed ID: 1827121
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
24. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.
Wun TC; Palmier MO; Siegel NR; Smith CE
J Biol Chem; 1989 May; 264(14):7862-8. PubMed ID: 2470735
[TBL] [Abstract][Full Text] [Related]
25. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
26. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
27. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Baker MS; Bleakley P; Woodrow GC; Doe WF
Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
[TBL] [Abstract][Full Text] [Related]
29. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells.
Mimuro J; Loskutoff DJ
J Biol Chem; 1989 Mar; 264(9):5058-63. PubMed ID: 2494180
[TBL] [Abstract][Full Text] [Related]
30. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.
Sherman PM; Lawrence DA; Yang AY; Vandenberg ET; Paielli D; Olson ST; Shore JD; Ginsburg D
J Biol Chem; 1992 Apr; 267(11):7588-95. PubMed ID: 1559996
[TBL] [Abstract][Full Text] [Related]
31. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
32. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR
Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805
[TBL] [Abstract][Full Text] [Related]
33. Measuring plasminogen activator inhibitor activity in plasma by two enzymatic assays.
Chiu WC; Gann DS; Darlington DN
J Biochem Biophys Methods; 2000 Sep; 45(2):127-40. PubMed ID: 10989129
[TBL] [Abstract][Full Text] [Related]
34. Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms.
Hekman CM; Loskutoff DJ
Biochemistry; 1988 Apr; 27(8):2911-8. PubMed ID: 2969749
[TBL] [Abstract][Full Text] [Related]
35. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
[TBL] [Abstract][Full Text] [Related]
36. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate.
Urano T; Strandberg L; Johansson LB; Ny T
Eur J Biochem; 1992 Nov; 209(3):985-92. PubMed ID: 1425706
[TBL] [Abstract][Full Text] [Related]
37. The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1.
Sarubbi E; Nolli ML; Robbiati F; Soffientini A; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):927-33. PubMed ID: 2512681
[TBL] [Abstract][Full Text] [Related]
38. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
39. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
Declerck PJ; De Mol M; Vaughan DE; Collen D
J Biol Chem; 1992 Jun; 267(17):11693-6. PubMed ID: 1601844
[TBL] [Abstract][Full Text] [Related]
40. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]